AstraZeneca has agreed to pay as much as $1.5 billion for the worldwide development and commercialization rights to Zegfrovy, an oral lung cancer medicine developed by China’s Dizal Pharmaceutical. Under the exclusive licensing agreement announced on July 14, 2026, AstraZeneca will pay $600 million upfront, with up to another $900 million tied to development, regulatory and sales milestones. Dizal will also receive tiered royalties on global sales.
The transaction is expected to close in the second half of 2026, subject to regulatory approvals and other customary conditions. AstraZeneca said the agreement would not affect its financial guidance for the year.
Zegfrovy, also known by its generic name sunvozertinib, is an irreversible epidermal growth factor receptor, or EGFR, inhibitor developed for genetically defined forms of non-small cell lung cancer. The drug is already approved in the United States and China for adults with locally advanced or metastatic disease whose tumours carry EGFR exon 20 insertion mutations and whose cancer has progressed during or after platinum-based chemotherapy.
AstraZeneca is therefore not paying for an early laboratory project with years of uncertain development ahead. It is acquiring a medicine that has already passed regulatory review in the world’s two largest pharmaceutical markets and generated commercial revenue.
That distinction helps explain the size of the upfront payment. In 2025, Dizal generated approximately 576 million yuan, or $85 million, in revenue from sunvozertinib, an increase of about 85% from the previous year. Shares in the Shanghai-listed biotechnology company rose 20% after the agreement was announced.
A difficult mutation with limited treatment options
Non-small cell lung cancer accounts for roughly 80% to 85% of lung cancer cases worldwide. EGFR mutations are considerably more common among Asian patients than among patients in the United States and Europe, but not all EGFR mutations respond equally well to existing targeted therapies.
Exon 20 insertion mutations are particularly difficult to treat. Their molecular structure can prevent conventional EGFR inhibitors from binding effectively to the target, while attempts to increase drug exposure may also damage healthy tissue carrying normal, or wild-type, EGFR.
Zegfrovy was designed to inhibit a broad range of cancer-driving EGFR mutations while showing greater selectivity for mutated EGFR over the normal form of the protein. The drug’s oral formulation also gives it a practical advantage over treatments requiring intravenous administration.
The opportunity is commercially attractive because the patient population is clearly identifiable through genetic testing, yet still has fewer targeted options than patients with more common EGFR mutations.
AstraZeneca already occupies a leading position in EGFR-mutated lung cancer through medicines including Tagrisso and Iressa. Adding Zegfrovy gives the company a product aimed at a mutation subgroup that is not adequately covered by conventional EGFR therapies. It may also allow AstraZeneca to create a more complete treatment portfolio across different stages, mutations and lines of therapy.
First-line data could expand the market
Zegfrovy is currently approved for patients who have already received platinum chemotherapy, but its largest commercial opportunity may lie in earlier treatment.
In the global Phase III WU-KONG28 study involving 324 patients, Zegfrovy achieved a median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy, when used as a first-line treatment for patients with EGFR exon 20 insertion-positive non-small cell lung cancer. Overall-survival data were not yet mature at the time of the analysis.
Dizal has submitted applications to the FDA and China’s Center for Drug Evaluation seeking approval in the first-line setting. Both regulators have granted the drug Breakthrough Therapy Designation for that use.
A first-line approval would substantially change the economics of the asset. Patients generally remain on treatment longer when a drug is used earlier, and the addressable population is larger because fewer patients have been lost to disease progression, declining health or competing therapies.
The $900 million milestone package is therefore likely linked not only to wider geographic approvals, but also to AstraZeneca’s ability to move Zegfrovy from a post-chemotherapy medicine into the initial treatment of the disease.
The clinical results are promising, but the drug is not without uncertainty. Progression-free survival improved relative to chemotherapy, yet mature overall-survival data will be needed to determine whether the treatment ultimately helps patients live longer. AstraZeneca will also have to compete with other targeted medicines and emerging combinations being developed for rare EGFR mutations.
A Chinese drug moving onto a global platform
The deal carries significance beyond AstraZeneca’s oncology pipeline. Dizal was established in 2017 as a spin-out from AstraZeneca’s China research operations. Nearly a decade later, AstraZeneca is paying a substantial premium to obtain worldwide rights to one of the company’s most successful medicines.
That history gives the transaction an unusual narrative. AstraZeneca helped create the environment from which Dizal emerged, but the Chinese biotechnology company independently advanced Zegfrovy through development, regulatory approval and commercialization before licensing the global rights back to its former parent.
It also illustrates how China’s pharmaceutical industry is changing. Earlier licensing transactions frequently involved experimental compounds with limited human data. Zegfrovy, by contrast, is a commercially validated product with approvals in China and the United States, Phase III evidence and an established revenue base.
Chinese drugmakers are increasingly exporting de-risked clinical and commercial assets rather than inexpensive early-stage molecules. That shift gives them greater negotiating power and allows them to demand larger upfront payments, milestone packages and royalties.
For AstraZeneca, the agreement is also consistent with its wider effort to deepen its relationship with China’s biotechnology sector. The company has recently signed several licensing and research transactions with Chinese pharmaceutical groups, using external innovation to supplement its internal pipeline.
China offers a large patient population, extensive clinical-development capacity and a growing pool of scientists experienced in targeted cancer medicines. Acquiring global rights to locally developed drugs gives multinational companies access to that innovation without having to discover every asset internally.
The real test begins after the deal
AstraZeneca’s global commercial network should give Zegfrovy access to markets that would be difficult for Dizal to enter alone. The British drugmaker has established regulatory, diagnostic and oncology sales infrastructure across more than 125 countries, as well as long-standing relationships with physicians treating EGFR-mutated lung cancer.
The challenge will be proving that the medicine can win a meaningful place in treatment guidelines outside China. AstraZeneca must support genetic testing for exon 20 insertions, secure reimbursement and persuade doctors that the drug offers a sufficiently strong balance of efficacy, convenience and safety.
The company will also have to determine how Zegfrovy fits alongside its existing lung cancer portfolio without creating unnecessary internal competition.
For Dizal, the transaction provides substantial non-dilutive capital while transferring the cost and complexity of global commercialization to a partner with far greater scale. The company retains exposure to future success through milestones and royalties rather than selling the asset outright.
The structure allows Dizal to monetize a mature product while continuing to benefit if AstraZeneca turns it into a global blockbuster.
For AstraZeneca, the $600 million upfront payment reflects confidence that Zegfrovy is more than a niche, late-line medicine. The full $1.5 billion value will only be justified if the company can win first-line approvals, expand the drug internationally and convert a genetically defined patient population into sustained global sales.
